What type of study is this?

September 10, 2025Journal of Clinical MedicineOpen Access

The Efficacy and Safety of Deferasirox Monotherapy as a Second-Line Treatment in Transfusion-Dependent Thalassemia with Iron Overload

View Full Paper

Ask AI

Bookmark

Serum ferritin levels significantly decreased from 2516 to 1027.5 ng/mL after treatment with deferasirox.
Half of the participants achieved target ferritin levels, indicating effective iron chelation in thalassemia patients.
Older patients with lower initial serum ferritin levels showed better response rates to DFX treatment.
The most common side effect reported was gastric irritation, occurring in 11.90% of cases.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Observational analysis demonstrated significant improvement in serum ferritin levels in patients with thalassemia, highlighting DFX's effectiveness as a second-line treatment.

Cite This Study

Pongamnuaykrit et al. (2025) studied this question.

synapsesocial.com/papers/68c1872d9b7b07f3a061180f https://doi.org/10.3390/jcm14176212

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis demonstrated significant improvement in serum ferritin levels in patients with thalassemia, highlighting DFX's effectiveness as a second-line treatment.

The Efficacy and Safety of Deferasirox Monotherapy as a Second-Line Treatment in Transfusion-Dependent Thalassemia with Iron Overload

Key Points

Discussion

Implication

Cite This Study

The Efficacy and Safety of Deferasirox Monotherapy as a Second-Line Treatment in Transfusion-Dependent Thalassemia with Iron Overload

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider